Literature DB >> 15708957

Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model.

Feilim Mac Gabhann1, Aleksander S Popel.   

Abstract

A comprehensive, biophysically accurate, computational model of vascular endothelial growth factor (VEGF) family member interactions with endothelial cell surface receptors was developed to study angiogenesis. Neuropilin-1 (NRP1) and the signaling VEGF receptor, VEGFR2, do not interact directly but are bridged by one VEGF isoform, VEGF(165). Using the model and published experimental data, we estimated the kinetic rate of this VEGFR2-NRP1 coupling in vitro. With the use of this rate, our model gives predictions in good quantitative agreement with several independent in vitro experiments involving VEGF(121) and VEGF(165) isoforms, confirming that VEGFR2-NRP1 coupling through VEGF(165) can fully explain the observed differences in receptor binding and phosphorylation in response to these isoforms. Model predictions also determine the mechanism of action of a commonly used NRP1 antibody and predict the results of potential future experiments. This is the first model to include VEGF isoforms or NRPs, and it is a necessary step toward a quantitative molecular level description of VEGF that can be extended to in vivo situations. The model has applications for both proangiogenic and antiangiogenic therapies, such as for heart disease and cancer, as well as in tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708957     DOI: 10.1152/ajpheart.01218.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  28 in total

Review 1.  Systems biology of the microvasculature.

Authors:  Lindsay E Clegg; Feilim Mac Gabhann
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

2.  Autologous morphogen gradients by subtle interstitial flow and matrix interactions.

Authors:  Mark E Fleury; Kendrick C Boardman; Melody A Swartz
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

3.  Stochastic models of receptor oligomerization by bivalent ligand.

Authors:  Tomás Alarcón; Karen M Page
Journal:  J R Soc Interface       Date:  2006-08-22       Impact factor: 4.118

4.  Mathematical models of the VEGF receptor and its role in cancer therapy.

Authors:  Tomás Alarcón; Karen M Page
Journal:  J R Soc Interface       Date:  2007-04-22       Impact factor: 4.118

5.  Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

6.  Analytical solution of steady-state equations for chemical reaction networks with bilinear rate laws.

Authors:  Adám M Halász; Hong-Jian Lai; Meghan McCabe Pryor; Krishnan Radhakrishnan; Jeremy S Edwards
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2013 Jul-Aug       Impact factor: 3.710

Review 7.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

8.  Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response.

Authors:  R Venkatasubramanian; R B Arenas; M A Henson; N S Forbes
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 9.  Systems biology of vascular endothelial growth factors.

Authors:  Feilim Mac Gabhann; Aleksander S Popel
Journal:  Microcirculation       Date:  2008-11       Impact factor: 2.628

10.  Coupled stochastic spatial and non-spatial simulations of ErbB1 signaling pathways demonstrate the importance of spatial organization in signal transduction.

Authors:  Michelle N Costa; Krishnan Radhakrishnan; Bridget S Wilson; Dionisios G Vlachos; Jeremy S Edwards
Journal:  PLoS One       Date:  2009-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.